A collaboration has been signed between the Bellvitge Biomedical Research Institute (IDIBELL), the Institute of Cancer Research (ICR) in London, and Vivan Therapeutics to jointly develop molecules that recognize more than one target for personalized treatment of colorectal cancer.
The local person in charge of the congress is Dra. Mònica Povedano, coordinator of the Motor Neuron Disease Functional Unit of the Bellvitge University Hospital (HUB) and principal researcher of the research group on Neurological and Neurogenetic Diseases of IDIBELL.
Researchers from the Respiratory Infections and Immunocompromised Host group at IDIBELL and the Bellvitge University Hospital have shown that monotherapy with a 3rd generation cephalosporin is effective and safe as a treatment for this serious infectious disease. These results will change international recommendations for its management.
Monotherapy could replace combination therapy in endocarditis Read More »
Thanks to the model, the IDIBELL team detected that one of the siblings had an additional genetic variant responsible for the greater severity of the pathology. These models offer the possibility of exploring each patient’s pathology and designing an individualized approach.
Accreditation was first obtained in 2021 and requires an annual review to verify that the necessary requirements are maintained.
The Clinical Research and Clinical Trials Unit obtains the ISO 9001:2015 recertification Read More »
The European EprObes project, which uses a methodology based on Artificial Intelligence, will study how to prevent obesity through early identification of biomarkers, risk factors, prognosis and intervention.
IDIBELL participates in a €10M European project to prevent childhood obesity Read More »
The project, promoted by IDIBELL and CNIO, together with seven other research institutes, will combine artificial intelligence with cutting-edge molecular biology techniques to provide predictive medicine tools to the National Health Service.
3.2 million euros to identify new genetic variants responsible for hereditary cancers Read More »
The journal New England Journal of Medicine has published the results of the NADIM II study, which confirms the great benefit of chemo-immunotherapy with nivolumab before surgery on locally advanced tumors and is consolidated worldwide as the standard of treatment.
This is a relevant position, endorsed by the scientific and care trajectory of Dr. Maria Molina, head of the Pneumology research group of the Institute of Bellvitge Biomedical Research.
The results of the study led by IDIBELL and the Hospital de Bellvitge solve a pending issue and open new ways to improve the patients’ life quality with safe and effective treatment.
